Emergent BioSolutions (EBS) to Hold Annual Meeting of Stockholders Thursday May 23, 2013 at 9:00 AM Eastern; Webcast Will be Available
5/16/2013 9:07:36 AM
More...
|
Emergent BioSolutions (EBS) to Webcast Presentation at Bank of America (BAC) Merrill Lynch 2013 Health Care Conference
5/9/2013 8:17:57 AM
More...
|
Emergent BioSolutions (EBS) Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer
5/3/2013 11:03:55 AM
More...
|
Emergent BioSolutions (EBS) Reports Financial Results for First Quarter 2013
5/3/2013 7:45:51 AM
More...
|
Emergent BioSolutions (EBS) to Webcast Presentation at Credit Suisse First Boston First Annual Antibody Day
4/29/2013 6:33:12 AM
More...
|
Why Emergent BioSolutions (EBS) Paid $26 Million for Anti-Chem Lotion From Bracco Diagnostics Inc.
4/26/2013 7:47:49 AM
More...
|
Emergent BioSolutions (EBS) Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases
4/11/2013 12:27:09 PM
More...
|
Emergent BioSolutions (EBS) Announces Positive Preclinical Efficacy and PK Data for its New Bispecific Adaptir Protein Therapeutic ES414 at American Association for Cancer Research
4/11/2013 6:57:33 AM
More...
|
Emergent BioSolutions (EBS) to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab Based on Strong Patient Enrollment and Encouraging Early Clinical Data
4/5/2013 9:50:39 AM
More...
|
Emergent BioSolutions (EBS) to Release First Quarter 2013 Financial Results and Conduct a Conference Call on May 2, 2013
4/4/2013 6:26:42 AM
More...
|
|